ClinicalTrials.gg
CompletedNCT03461276Updated May 5, 2026Results posted

Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD

A Phase 2 interventional study of ABvac40 and Placebo in Mild Cognitive Impairment and Alzheimer Disease, sponsored by Araclon Biotech S.L.. Completed at 23 sites in 4 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Araclon Biotech S.L. (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Cognitive Dysfunction with a site in Spain — 43 open to participants now, 60 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.

Enrollment
47th of 126
134 · median 100
Started
2017
with 6 others
Phase 2
15 of 161
1 open now
Registered
29th of 161
by date

Among the 161 studies in Cognitive Dysfunction with a site in Spain, this one is the 47th largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2017, is one of 15 in phase 2, and was the 29th registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,122 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

43 of the 161 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Cognitive Dysfunction with a site in Spain, or all of them as a file.
02

Study summary

Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide. The amyloid cascade hypothesis of AD proposes that amyloid-β (Aβ) peptide accumulation in the brain, caused by an imbalance between Aβ production and clearance, is the initiating factor of a cascade ultimately leading to dementia.

Aβ peptides are generated from sequential cleavage of the amyloid precursor protein (APP), including Aβ40 and Aβ42. Aβ40 is the predominant variant (90%) among the secreted Aβ forms and although Aβ42 is more hydrophobic and prone to aggregate, and Aβ42 oligomers are regarded to be the most neurotoxic species, Aβ40 can also produce highly toxic diffusible aggregates, which can be prevented in vitro by specific anti-Aβ40 antibodies.

Several studies have proposed that a high concentration of Aβ40 in the brain distinguishes patients with AD from those who have senile plaques but are cognitively normal, pointing to the importance of Aβ40 in the onset of dementia. In keeping with this, previous studies have demonstrated that specific anti-Aβ40 antibodies label NFTs in the entorhinal cortex and the hippocampus of AD brains, and that these do not co-localize with tau NFTs, suggesting the presence of degenerating neuronal populations filled with C-terminal fragments of Aβx-40. In addition, Aβ40 is the main component of amyloid deposition around cerebral arteries causing cerebral amyloid angiopathy (CAA), which has a prevalence of about 80-90% in patients with AD (for more information see Lacosta et al. Alzheimer's Research \& Therapy (2018) 10:12 DOI 10.1186/s13195-018-0340-8).

Considering those previous results suggesting that strategies targeting Aβ40 could represent novel disease-modifying therapies, we have developed ABvac40, the first active vaccine targeting the C-terminal end of the Aβ40 peptide.

The purpose of this Phase II study is to confirm in patients with a-MCI or vm-AD the level of safety and tolerability obtained in the ABvac40 Phase I clinical trial in patients with mm-AD. In addition, the study is aimed to better characterize the immune response elicited by ABvac40 and to explore its effects on AD biomarkers.

03

Conditions studied

  • Mild Cognitive Impairment
  • Alzheimer Disease
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject must meet all the following inclusion criteria:

  1. Male or female between 55 and 80 years of age, both inclusive, at the time of signing .
  2. The patient (or legal representative, if applicable) and a close relative/caregiver must read the subject information sheet, agree to participate in the clinical trial and sign the informed consent form (the patient and a close relative/caregiver).
  3. Presence of a stable caregiver to attend the patient study visits.
  4. Mini-Mental Status Examination () score between 24 and 30 points (inclusive), according to age and education level.
  5. Clinical Dementia Rating (CDR) scale scoring 0.5.
  6. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score on the Delayed Memory Index (DMI) of 85 or lower.
  7. The results of the patient's MRI brain scan must be concordant with the diagnosis of clinical a-MCI or vm-AD according to the following criteria: Scheltens scale, and measurement of white matter and past haemorrhages.
  8. If the patient is receiving treatment for AD, must have been stable during the two months before the selection visit.
  9. Treatment for concomitant diseases must be stable during the previous month before the treatment of the study.
  10. Positive assessment of the candidate by the investigator for complying with the requirements and procedures of the study.

Exclusion criteria

Exclusion Criteria:

A subject meeting any of the following exclusion criteria is NOT eligible for participation in the study.

  1. Known allergy to components of the vaccine or prior history of anaphylaxis, a severe allergic reaction or a history of to any component of the formulation. Allergy to fish or shellfish.
  2. Active infectious disease (i.e. , C). Positive syphilis serology.
  3. History or presence of disease, except mild eczema, rhinitis or psoriasis.
  4. Presence or history of immunodeficiency (i.e. ).
  5. Significant kidney and/or liver disease.
  6. History of asthma or reactive airway disease with bronchospasm in the last 6 months, or currently on regular treatment.
  7. Major uncontrolled systemic condition (e.g. diabetes, congestive heart failure, hypertension).
  8. History of cancer (≤5 years since the last specific treatment). Exceptions: basocellular carcinoma.
  9. Significant alterations in hematological, biochemical or urine analytical parameters, particularly those relating to levels of vitamin B12, folic acid or thyroid tests.
  10. History of any other central nervous system disorder, degenerative or non-degenerative neurological or psychiatric condition that, in the investigator's opinion could be the cause of the dementia, or could explain the cognitive impairment, or that might interfere with cognitive function directly or by its treatment.
  11. Geriatric Depression Scale (GDS; abbreviated version), score >5
  12. Has a "yes" answer to C-SSRS suicidal ideation items 4 or 5, or any suicidal behavior within 6 months before Screening, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening.
  13. History or signs of cerebrovascular disease (ischemic or haemorrhagic stroke, ), or diagnosis of possible, probable or clear vascular dementia according to NINDS-AIREN criteria.
  14. Presence on MRI of a relevant pattern of microvascular disease (Leukoaraiosis, Fazekas score ≥2 in the deep white matter scale or ≥4 in the global score) or more than one lacunar or territorial infarcts. Any other MRI finding that, in the opinion of the investigator, might be a relevant contributing cause of subject´s cognitive impairment. Presence of up to 3 microhemorrhages will be acceptable.
  15. History of bleeding disorder or predisposing conditions, blood clotting or abnormal results on coagulation profile at Screening, as determined by the Investigator.
  16. Patients being treated with anticoagulants or antiaggregant therapy (aspirin at a prophylactic dose ≤ 325 mg daily or clopidogrel at a dose ≤75 mg daily are allowed) should not be recruited in the study.
  17. Modified Hachinski Ischemic Scale, score higher than 4.
  18. Surgery (with general anaesthetic) within the previous three months to be included in the trial or programed during the study period.
  19. Treatment within 30 days prior to visit 0 with systemic or other 's.
  20. Vaccination against influenza or any other vaccination within 2 months before first IMP dose.
  21. Patients, who have previously been randomized in this trial.
  22. Participation in another clinical trial within the previous 1 month to screening visit, or within the previous 12 months after the last dose to the screening visit in the case of subjects who participated in trials with a study drug whose intention was to modify the progression AD unless documentation of receipt of placebo is available. The patient cannot be included in the study if the experimental drug was an immunotherapeutic drug, including IVIG or a vaccine against Alzheimer's disease unless documentation of receipt of placebo is available.
  23. Patients with alcohol or drug abuse or dependence.
  24. Absolute (having a pacemaker or implantable defibrillator) or relative (bare metal stent or stent implanted in the last six months) to MRI examination. Feeling of claustrophobic do not let perform MRI or PET scan.
  25. Patients unlikely to comply with the protocol (e.g., unable to return for follow-up visits).
  26. Women of , pregnant or nursing.
  27. Significant alterations in the that are associated with an added risk for the patient.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    ABvac40

    Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.

    Biological: ABvac40

  • Placebo comparator
    Placebo

    Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.

    Biological: Placebo

Interventions

  • BiologicalABvac40

    ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminum hydroxide as adjuvant.

  • BiologicalPlacebo

    Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminum hydroxide) without the conjugate.

06

What researchers measure

Primary outcomes

  1. Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA)

    Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit.

    Time frame: Part A (Baseline, and post-Baseline visits at Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

Secondary outcomes

  1. Subject Discontinuations Due to TEAEs

    Number of withdrawn subjects due to treatment-emergent adverse events (TEAEs) during the whole study.

    Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)

  2. Number of Subjects With Clinically Significant Abnormalities in Physical Examination

    Clinically significant (CS) abnormalities in physical examination reported during the study.

    Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)

  3. Number of Subjects With Clinically Significant Abnormalities in Neurological Examination

    Clinically significant (CS) abnormalities in neurological examination reported during the study.

    Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)

  4. Number of Subjects With Clinically Significant Abnormalities in Analytical Hematology

    Clinically significant (CS) abnormalities in hematology parameters reported during the study.

    Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)

  5. Number of Subjects With Clinically Significant Abnormalities in Analytical Biochemistry

    Clinically significant (CS) abnormalities in biochemistry parameters reported during the study.

    Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)

  6. Number of Subjects With Clinically Significant Abnormalities in Coagulation

    Clinically significant (CS) abnormalities in coagulation parameters reported during the study.

    Time frame: Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)

  7. Level of Anti-Aβ40 Antibodies in CSF

    The change in levels of anti-Aβ40 antibodies in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  8. Level of Anti-Aβ40 Antibodies in Plasma

    The change in levels of anti-Aβ40 antibodies in plasma from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

  9. Level of Antibody-secreting Cells

    The change in levels of antibody-secreting cells from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

  10. Level of Aβ40 Peptides in Plasma - ABtest-IA

    The change in levels of anti-Aβ40 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

  11. Level of Aβ42 Peptides in Plasma - ABtest-IA

    The change in levels of anti-Aβ42 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

  12. Level of Aβ40 Peptides in Plasma - ABtest-MS

    The change in levels of anti-Aβ40 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

  13. Level of Aβ42 Peptides in Plasma - ABtest-MS

    The change in levels of anti-Aβ42 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

  14. Cortical Fibrillary Amyloid Deposition Assessed by a-PET Scans

    The change in amyloid-PET (a-PET) standard centiloid global cortical area (reference Pons) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  15. Percentage of Change in Brain Volume

    The percent change in brain volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, and Week 104A)

  16. Percentage of Change in Hippocampal Volume

    The percent change in right and left hippocampal volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, Week 104A)

  17. Percentage of Change in Ventricular Volume

    The percent change in ventricular volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, and Week 104A)

  18. Level of Aβ42 Peptides in CSF

    The change in levels of Aβ42 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  19. Level of Aβ40 Peptides in CSF

    The change in levels of Aβ40 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  20. Aβ42/Aβ40 Ratio in CSF

    The change in Aβ42/Aβ40 ratio in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  21. Level of Total Tau in CSF

    The change in levels of total Tau in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  22. Level of p-Tau 181 in CSF

    The change in levels of p-Tau 181 in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  23. Level of Neurofilament Light in CSF

    The change in levels of neurofilament light in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  24. Level of Neurogranin in CSF

    The change in levels of neurogranin in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  25. Mini Mental State Examination (MMSE) Score

    The change in MMSE score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. MMSE is an 11-question measure that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall, and language. MMSE score ranges: 0-30, with lower scores indicating worst cognition. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (baseline, and post-baseline at Week 24A, Week 50A, Week 77A, and Week 104A)

  26. Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score

    The change in CDR-SB score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. CDR-SB assesses 6 cognitive and functional domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, Personal Care. CDR-SB score ranges: 0-18. The higher scores mean a worst outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)

  27. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score

    The change in RBANS total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. RBANS assesses 5 cognitive domains: Immediate Memory, Visuospatial/constructional, Language, Attention, Delayed Memory. Total score (range 40-160) sums the 5 domain scores. The higher scores mean a better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)

  28. Alzheimer's Disease Cooperative Study - Activities of Daily Living, Mild Cognitive Impairment (ADCS-ADL MCI) Score

    The change in ADCS-ADL MCI total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. ADCS-ADL MCI is a 24-item scale that includes 6 basic activities of daily living (ADL) items and 16 instrumental ADL items that provide a total score: 0-78, with a lower score indicating greater severity. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)

  29. Trail Making Test (TMT) Scores

    Change in TMT score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. TMT has 2 parts in which the patient connects 25 dots in order as quickly as possible. In TMT-A, targets are numbers 1-25; in TMT-B, targets are numbers 1-13 interleaved with letters A-L. Lower timings indicate better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)

  30. Investigator Global Evaluation (IGE) Score

    Change in IGE from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. IGE at baseline:1-Good general status;2-Slight deterioration;3-Moderate deterioration;4-Bad general status. IGE after baseline:1-Marked improvement;2-Moderate improvement;3-Slight improvement;4-No change;5-Slight worsening;6-Moderate worsening;7-Marked worsening. MMRM included IGE after baseline as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix is used. Following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly significantly associated with response measure (p \< 0.15).

    Time frame: Part A (Week 24A, Week 50A, and Week 104A)

  31. Columbia Suicide Severity Rating Scale

    Subjects with suicidal ideation or suicidal behavior since last visit.

    Time frame: Part A (Week 24A, Week 50A, Week 77A, and Week 104A)

  32. EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Overall Severity Index Score

    Change in EQ-5D-5L overall severity index from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. EQ-5D-5L has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression; rated: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

  33. EuroQol 5 Dimensions 5 Levels - Visual Analogue Scale (EQ-5D-5L - VAS) Score

    The change in EQ-5D-5L - VAS score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. VAS records the patient's self-rated health on a vertical scale, ranging from 100 = 'Best imaginable health state' down to 0 = 'Worst imaginable health state'. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

    Time frame: Part A (Week 50A and Week 104A)

Other outcomes

  1. Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) - Sensitivity

    Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit. Sensitivity analyses in the PP (Part A) analysis set.

    Time frame: Part A (Baseline, and post-Baseline visits at Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)

07

Results

Posted Feb 3, 2025

Participant flow

A total of 23 centers in Spain (n=18), France (n=3), Italy (n=1) and Sweden (n=1) recruited subjects in this study. The subjects' recruitment was competitive until the required number of subjects was completed.

Part A (18-24 months duration)
Participant flow — Part A (18-24 months duration)
MilestonePlacebo Arm Part A/ABvac40 Arm Part BABvac40 Arm Part A/Placebo+Booster Arm Part B
Started6262
Completed5355
Not completed97
Withdrew: Adverse event, serious fatal11
Withdrew: Physician decision10
Withdrew: Withdrawal by subject11
Withdrew: Adverse event, non-fatal31
Withdrew: Patient heath status01
Withdrew: Patient/caregiver's decision33
Part B (18 months duration)
Participant flow — Part B (18 months duration)
MilestonePlacebo Arm Part A/ABvac40 Arm Part BABvac40 Arm Part A/Placebo+Booster Arm Part B
Started3740
Completed3338
Not completed42
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01
Withdrew: Adverse event, non-fatal01
Withdrew: Patient/caregiver's decision30

Outcome measures

PrimaryAverage Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA)

Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit.

Time frame:
Part A (Baseline, and post-Baseline visits at Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Mean · OD
Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA)
ODPlacebo Arm Part AABvac40 Arm Part A
Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA)0.12 ± 0.213.27 ± 0.75
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · t-test, 1 sided · p = <0.0001A 1-sided t-test with a significance level of 0.025 was employed.
  • Placebo Arm Part A vs ABvac40 Arm Part A · Wilcoxon (Mann-Whitney) · p = <0.0001 (1-sided)
  • Placebo Arm Part A vs ABvac40 Arm Part A · ANCOVA · p = <0.0001 · Mean difference (final values): 3.15 · 95% CI 2.96 to 3.34
  • Placebo Arm Part A vs ABvac40 Arm Part A · t-test, 1 sided · p = <0.0001t-test (sensitivity hypothesis). A 1-sided t-test with a significance level of 0.025 was employed.
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = <0.05
SecondarySubject Discontinuations Due to TEAEs

Number of withdrawn subjects due to treatment-emergent adverse events (TEAEs) during the whole study.

Time frame:
Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Reported as:
Count of participants · Participants
Subject Discontinuations Due to TEAEs
ParticipantsPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Subject Discontinuations Due to TEAEs4201
SecondaryNumber of Subjects With Clinically Significant Abnormalities in Physical Examination

Clinically significant (CS) abnormalities in physical examination reported during the study.

Time frame:
Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormalities in Physical Examination
ParticipantsPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Number of Subjects With Clinically Significant Abnormalities in Physical Examination4142
SecondaryNumber of Subjects With Clinically Significant Abnormalities in Neurological Examination

Clinically significant (CS) abnormalities in neurological examination reported during the study.

Time frame:
Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormalities in Neurological Examination
ParticipantsPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Number of Subjects With Clinically Significant Abnormalities in Neurological Examination6521
SecondaryNumber of Subjects With Clinically Significant Abnormalities in Analytical Hematology

Clinically significant (CS) abnormalities in hematology parameters reported during the study.

Time frame:
Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormalities in Analytical Hematology
ParticipantsPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Number of Subjects With Clinically Significant Abnormalities in Analytical Hematology5406
SecondaryNumber of Subjects With Clinically Significant Abnormalities in Analytical Biochemistry

Clinically significant (CS) abnormalities in biochemistry parameters reported during the study.

Time frame:
Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormalities in Analytical Biochemistry
ParticipantsPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Number of Subjects With Clinically Significant Abnormalities in Analytical Biochemistry12566
SecondaryNumber of Subjects With Clinically Significant Abnormalities in Coagulation

Clinically significant (CS) abnormalities in coagulation parameters reported during the study.

Time frame:
Entire study duration (Week 0 to Week 104 in Part A, and Week 0 to Week 77 in Part B)
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormalities in Coagulation
ParticipantsPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Number of Subjects With Clinically Significant Abnormalities in Coagulation4132
SecondaryLevel of Anti-Aβ40 Antibodies in CSF

The change in levels of anti-Aβ40 antibodies in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · ng/mL
Level of Anti-Aβ40 Antibodies in CSF
ng/mLPlacebo Arm Part AABvac40 Arm Part A
Week 50A0.1654 ± 3.8650230.1826 ± 3.90756
Week 104A0.2014 ± 0.367531.2437 ± 0.41902
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = <0.001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.047
SecondaryLevel of Anti-Aβ40 Antibodies in Plasma

The change in levels of anti-Aβ40 antibodies in plasma from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · μg/mL
Level of Anti-Aβ40 Antibodies in Plasma
μg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 2A1.5580 ± 4.221001.5112 ± 4.40221
Week 6A1.5580 ± 4.2210013.7052 ± 4.44801
Week 10A1.6172 ± 4.2427644.3187 ± 4.41509
Week 14A1.5479 ± 4.2427662.1946 ± 4.43781
Week 18A1.5789 ± 4.3074669.8861 ± 4.43781
Week 24A1.5926 ± 4.2643239.9483 ± 4.44151
Week 40A1.6027 ± 4.3326414.6139 ± 4.48526
Week 44A1.5463 ± 4.3526757.5771 ± 4.48568
Week 50A1.5993 ± 4.3536333.5366 ± 4.51418
Week 77A1.5232 ± 4.3773510.8197 ± 4.57100
Week 104A1.7400 ± 5.5774310.8365 ± 5.82224
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9936
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0391 (MMRM - Week 6A)
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0299
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1267
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2477
SecondaryLevel of Antibody-secreting Cells

The change in levels of antibody-secreting cells from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included the recorded outcome value as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · SFU/0.5x10^6 PBMCs
Level of Antibody-secreting Cells
SFU/0.5x10^6 PBMCsPlacebo Arm Part AABvac40 Arm Part A
Week 2A-0.4596 ± 0.376700.1943 ± 0.34478
Week 6A-0.1172 ± 0.723662.3198 ± 0.67598
Week 10A0.2730 ± 0.783084.0542 ± 0.72897
Week 14A-0.1929 ± 1.447467.5160 ± 1.36639
Week 18A0.2480 ± 1.028146.9016 ± 0.93531
Week 24A0.4532 ± 0.737443.6179 ± 0.67779
Week 40A-0.5655 ± 0.428861.2534 ± 0.38540
Week 44A-1.2538 ± 2.4567710.1860 ± 2.23291
Week 50A-0.3314 ± 1.069614.6143 ± 1.00245
Week 77A-0.4495 ± 0.520991.8385 ± 0.47208
Week 104A0.1758 ± 0.418890.3735 ± 0.41451
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1956
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0152
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0006
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0002
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0020
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0018
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0008
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0010
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0014
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.7357
SecondaryLevel of Aβ40 Peptides in Plasma - ABtest-IA

The change in levels of anti-Aβ40 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Aβ40 Peptides in Plasma - ABtest-IA
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 2A3.8381 ± 2.150404.0604 ± 2.15734
Week 6A4.5019 ± 2.575618.9863 ± 2.56744
Week 10A5.5195 ± 3.38710-2.7073 ± 3.37532
Week 14A6.0407 ± 4.73576-9.9564 ± 4.72351
Week 18A8.9690 ± 4.67231-12.7882 ± 4.63367
Week 24A7.6033 ± 4.05399-30.0419 ± 4.02351
Week 40A5.9903 ± 4.72341-42.6835 ± 4.64278
Week 44A8.6825 ± 5.47731-36.1069 ± 5.37898
Week 50A7.7553 ± 5.58033-36.3509 ± 5.47307
Week 77A11.2896 ± 5.12501-31.1947 ± 5.03820
Week 104A9.1909 ± 7.62291-15.8591 ± 7.65813
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9386
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2019
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0810
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0171
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0011
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0216
SecondaryLevel of Aβ42 Peptides in Plasma - ABtest-IA

The change in levels of anti-Aβ42 peptides in plasma (ABtest-IA) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Aβ42 Peptides in Plasma - ABtest-IA
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 2A0.6745 ± 0.476900.3868 ± 0.47126
Week 6A1.2776 ± 0.773581.6248 ± 0.76131
Week 10A1.2091 ± 0.885762.1331 ± 0.87167
Week 14A1.6433 ± 0.739751.0209 ± 0.72987
Week 18A1.9821 ± 0.554651.2815 ± 0.54507
Week 24A2.8599 ± 0.724521.6125 ± 0.71101
Week 40A2.0361 ± 0.84268-1.2781 ± 0.81992
Week 44A1.7850 ± 1.00896-0.9785 ± 0.98520
Week 50A2.6958 ± 1.244600.5563 ± 1.21767
Week 77A2.9304 ± 1.153920.9045 ± 1.13274
Week 104A0.8402 ± 1.364270.5027 ± 1.34946
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.6515
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.7447
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.4518
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.5416
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.3504
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2109
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0049
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0498
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2181
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2087
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8599
SecondaryLevel of Aβ40 Peptides in Plasma - ABtest-MS

The change in levels of anti-Aβ40 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. A compound symmetric variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Aβ40 Peptides in Plasma - ABtest-MS
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 2A15.0554 ± 86.193647.2235 ± 87.23687
Week 6A12.9981 ± 86.1936426.8351 ± 87.24290
Week 10A10.8314 ± 86.57079123.0016 ± 87.42725
Week 14A10.1449 ± 86.57079277.9974 ± 87.75818
Week 18A10.1987 ± 87.66045397.6406 ± 88.10607
Week 24A31.0861 ± 86.93514453.1893 ± 88.16061
Week 40A-26.9761 ± 88.54373377.7762 ± 88.44661
Week 44A-28.4349 ± 88.50690846.1633 ± 88.82717
Week 50A-34.2153 ± 88.91637628.9483 ± 88.88059
Week 77A-30.9656 ± 89.32946155.5480 ± 89.69327
Week 104A-37.3585 ± 110.4832985.9804 ± 113.05734
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9469
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9063
  • Placebo Arm Part A · Mixed Models Analysis · p = = 0.3418
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0236
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0012
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0004
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0008
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1255
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.4234
SecondaryLevel of Aβ42 Peptides in Plasma - ABtest-MS

The change in levels of anti-Aβ42 peptides in plasma (ABtest-MS) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Aβ42 Peptides in Plasma - ABtest-MS
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 2A-0.2211 ± 1.22162-0.0175 ± 1.22543
Week 6A-0.2339 ± 1.325821.7627 ± 1.32847
Week 10A-1.1074 ± 1.322260.8282 ± 1.32090
Week 14A0.0854 ± 1.143690.4418 ± 1.15082
Week 18A0.5632 ± 1.51032-0.9906 ± 1.49756
Week 24A-0.1341 ± 1.37466-1.6456 ± 1.37921
Week 40A2.8714 ± 1.708453.3146 ± 1.68116
Week 44A1.5116 ± 1.518171.9216 ± 1.49840
Week 50A0.1124 ± 1.487872.6909 ± 1.46207
Week 77A1.3886 ± 1.611564.6804 ± 1.58811
Week 104A4.6921 ± 2.188292.6075 ± 2.19973
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9031
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2749
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2874
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8191
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.4559
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.4259
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8508
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8443
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2075
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1400
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.4985
SecondaryCortical Fibrillary Amyloid Deposition Assessed by a-PET Scans

The change in amyloid-PET (a-PET) standard centiloid global cortical area (reference Pons) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · Centiloids
Cortical Fibrillary Amyloid Deposition Assessed by a-PET Scans
CentiloidsPlacebo Arm Part AABvac40 Arm Part A
Week 50A1.411 ± 1.12033.561 ± 1.0918
Week 104A4.461 ± 1.38411.241 ± 1.5403
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1058
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0922
SecondaryPercentage of Change in Brain Volume

The percent change in brain volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, and Week 104A)
Reported as:
Least squares mean · percent change
Percentage of Change in Brain Volume
percent changePlacebo Arm Part AABvac40 Arm Part A
Week 24A-1.39 ± 0.157-1.40 ± 0.165
Week 50A-2.05 ± 0.175-1.75 ± 0.187
Week 104A-4.16 ± 0.470-3.11 ± 0.412
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9313
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2243
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0952
SecondaryPercentage of Change in Hippocampal Volume

The percent change in right and left hippocampal volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, Week 104A)
Reported as:
Least squares mean · percent change
Percentage of Change in Hippocampal Volume
percent changePlacebo Arm Part AABvac40 Arm Part A
Week 24A - left-1.63 ± 0.450-2.17 ± 0.449
Week 50A - left-4.16 ± 0.582-4.26 ± 0.568
Week 104A - left-7.17 ± 1.055-8.18 ± 0.962
Week 24A - right-1.37 ± 0.442-1.44 ± 0.439
Week 50A - right-3.34 ± 0.513-3.23 ± 0.506
Week 104A - right-6.37 ± 1.001-6.49 ± 0.901
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.3647
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8962
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.4781
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9095
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8744
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9307
SecondaryPercentage of Change in Ventricular Volume

The percent change in ventricular volume from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, and Week 104A)
Reported as:
Least squares mean · percent change
Percentage of Change in Ventricular Volume
percent changePlacebo Arm Part AABvac40 Arm Part A
Week 24A5.30 ± 0.5845.94 ± 0.573
Week 50A10.63 ± 0.80910.21 ± 0.819
Week 104A22.51 ± 1.88721.26 ± 1.848
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.3982
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.7035
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.6334
SecondaryLevel of Aβ42 Peptides in CSF

The change in levels of Aβ42 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Aβ42 Peptides in CSF
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 50A29.0 ± 19.40-2.0 ± 19.79
Week 104A-15.3 ± 22.514.0 ± 25.82
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2193
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.5543
SecondaryLevel of Aβ40 Peptides in CSF

The change in levels of Aβ40 peptides in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Aβ40 Peptides in CSF
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 50A-62.3 ± 173.57-141.8 ± 180.07
Week 104A-652.4 ± 227.08-192.5 ± 260.67
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.7324
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1719
SecondaryAβ42/Aβ40 Ratio in CSF

The change in Aβ42/Aβ40 ratio in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · Ratio
Aβ42/Aβ40 Ratio in CSF
RatioPlacebo Arm Part AABvac40 Arm Part A
Week 50A0.0007 ± 0.001340.0009 ± 0.00129
Week 104A0.0018 ± 0.001820.0021 ± 0.00204
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9262
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9173
SecondaryLevel of Total Tau in CSF

The change in levels of total Tau in cerebrospinal fluid (CSF) from baseline to each applicable postbaseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Total Tau in CSF
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 50A26.2 ± 12.0817.8 ± 12.40
Week 104A27.6 ± 14.2515.9 ± 16.43
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9220
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.5763
SecondaryLevel of p-Tau 181 in CSF

The change in levels of p-Tau 181 in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of p-Tau 181 in CSF
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 50A2.84 ± 1.6643.14 ± 1.696
Week 104A1.97 ± 2.3860.80 ± 2.646
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8917
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.7350
SecondaryLevel of Neurofilament Light in CSF

The change in levels of neurofilament light in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Neurofilament Light in CSF
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 50A59.36 ± 76.513181.20 ± 78.606
Week 104A317.11 ± 190.948276.14 ± 216.781
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2283
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.886
SecondaryLevel of Neurogranin in CSF

The change in levels of neurogranin in cerebrospinal fluid (CSF) from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · pg/mL
Level of Neurogranin in CSF
pg/mLPlacebo Arm Part AABvac40 Arm Part A
Week 50A-4.69 ± 8.023-5.93 ± 8.328
Week 104A-34.97 ± 13.533-31.13 ± 15.571
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.909
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8498
SecondaryMini Mental State Examination (MMSE) Score

The change in MMSE score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. MMSE is an 11-question measure that tests 5 areas of cognitive function: orientation, registration, attention and calculation, recall, and language. MMSE score ranges: 0-30, with lower scores indicating worst cognition. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (baseline, and post-baseline at Week 24A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · score on a scale
Mini Mental State Examination (MMSE) Score
score on a scalePlacebo Arm Part AABvac40 Arm Part A
Week 24A-2.15 ± 0.422-2.24 ± 0.420
Week 50A-3.64 ± 0.465-2.65 ± 0.460
Week 77A-4.58 ± 0.628-4.15 ± 0.621
Week 104A-5.98 ± 0.816-4.97 ± 0.816
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8711
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1098
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.6179
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.3715
SecondaryClinical Dementia Rating-Sum of Boxes (CDR-SB) Score

The change in CDR-SB score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. CDR-SB assesses 6 cognitive and functional domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, Personal Care. CDR-SB score ranges: 0-18. The higher scores mean a worst outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · score on a scale
Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score
score on a scalePlacebo Arm Part AABvac40 Arm Part A
Week 24A0.75 ± 0.1520.73 ± 0.156
Week 50A1.41 ± 0.2221.36 ± 0.221
Week 77A2.12 ± 0.3282.05 ± 0.325
Week 104A3.21 ± 0.4632.90 ± 0.462
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8949
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8712
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8748
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.6402
SecondaryRepeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score

The change in RBANS total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. RBANS assesses 5 cognitive domains: Immediate Memory, Visuospatial/constructional, Language, Attention, Delayed Memory. Total score (range 40-160) sums the 5 domain scores. The higher scores mean a better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · score on a scale
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score
score on a scalePlacebo Arm Part AABvac40 Arm Part A
Week 24A-1.30 ± 1.009-2.10 ± 1.022
Week 50A-5.45 ± 1.076-5.56 ± 1.077
Week 77A-4.71 ± 1.273-2.66 ± 1.255
Week 104A-3.17 ± 1.798-1.33 ± 1.793
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.552
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9371
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2354
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.4608
SecondaryAlzheimer's Disease Cooperative Study - Activities of Daily Living, Mild Cognitive Impairment (ADCS-ADL MCI) Score

The change in ADCS-ADL MCI total score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. ADCS-ADL MCI is a 24-item scale that includes 6 basic activities of daily living (ADL) items and 16 instrumental ADL items that provide a total score: 0-78, with a lower score indicating greater severity. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · score on a scale
Alzheimer's Disease Cooperative Study - Activities of Daily Living, Mild Cognitive Impairment (ADCS-ADL MCI) Score
score on a scalePlacebo Arm Part AABvac40 Arm Part A
Week 24A-0.99 ± 0.834-2.08 ± 0.844
Week 50A-4.15 ± 1.124-3.78 ± 1.112
Week 77A-6.33 ± 1.399-6.54 ± 1.380
Week 104A-9.87 ± 2.002-10.02 ± 1.982
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.3246
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.8047
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.916
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9582
SecondaryTrail Making Test (TMT) Scores

Change in TMT score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a MMRM and the ITT analysis set. TMT has 2 parts in which the patient connects 25 dots in order as quickly as possible. In TMT-A, targets are numbers 1-25; in TMT-B, targets are numbers 1-13 interleaved with letters A-L. Lower timings indicate better outcome. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Reported as:
Least squares mean · seconds
Trail Making Test (TMT) Scores
secondsPlacebo Arm Part AABvac40 Arm Part A
Week 24A - Trail A0.54 ± 2.960-0.59 ± 2.939
Week 50A - Trail A11.34 ± 4.1863.59 ± 4.023
Week 77A - Trail A17.42 ± 4.6692.79 ± 4.425
Week 104A - Trail A20.09 ± 7.2539.24 ± 6.967
Week 24A - Trail B5.43 ± 8.102-8.47 ± 8.464
Week 50A - Trail B18.83 ± 8.50318.43 ± 9.122
Week 77A - Trail B17.13 ± 8.6802.38 ± 9.762
Week 104A - Trail B20.81 ± 10.715-4.64 ± 11.206
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.777
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1727
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.0218
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2789
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2261
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9743
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2556
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.1008
SecondaryInvestigator Global Evaluation (IGE) Score

Change in IGE from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. IGE at baseline:1-Good general status;2-Slight deterioration;3-Moderate deterioration;4-Bad general status. IGE after baseline:1-Marked improvement;2-Moderate improvement;3-Slight improvement;4-No change;5-Slight worsening;6-Moderate worsening;7-Marked worsening. MMRM included IGE after baseline as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix is used. Following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly significantly associated with response measure (p \< 0.15).

Time frame:
Part A (Week 24A, Week 50A, and Week 104A)
Reported as:
Least squares mean · score on a scale
Investigator Global Evaluation (IGE) Score
score on a scalePlacebo Arm Part AABvac40 Arm Part A
Week 24A4.02 ± 0.0754.07 ± 0.077
Week 50A4.26 ± 0.1014.21 ± 0.101
Week 104A4.55 ± 0.1804.45 ± 0.184
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.6189
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.6937
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.6981
SecondaryColumbia Suicide Severity Rating Scale

Subjects with suicidal ideation or suicidal behavior since last visit.

Time frame:
Part A (Week 24A, Week 50A, Week 77A, and Week 104A)
Reported as:
Count of participants · Participants
Columbia Suicide Severity Rating Scale
ParticipantsPlacebo Arm Part AABvac40 Arm Part A
Week 24A - suicidal ideation11
Week 24A - suicidal behavior00
Week 50A - suicidal ideation12
Week 50A - suicidal behavior00
Week 77A - suicidal ideation14
Week 77A - suicidal behavior00
Week 104A - suicidal ideation00
Week 104A - suicidal behavior00
SecondaryEuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Overall Severity Index Score

Change in EQ-5D-5L overall severity index from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using MMRM and ITT analysis set. EQ-5D-5L has 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression; rated: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · score on a scale
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Overall Severity Index Score
score on a scalePlacebo Arm Part AABvac40 Arm Part A
Week 50A-0.99 ± 1.204-2.71 ± 1.196
Week 104A-3.06 ± 1.740-0.92 ± 1.725
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.2863
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.3703
SecondaryEuroQol 5 Dimensions 5 Levels - Visual Analogue Scale (EQ-5D-5L - VAS) Score

The change in EQ-5D-5L - VAS score from baseline to each applicable post-baseline efficacy visit (Part A) was analyzed using a Mixed-Model Repeated Measures (MMRM), and the ITT analysis set. VAS records the patient's self-rated health on a vertical scale, ranging from 100 = 'Best imaginable health state' down to 0 = 'Worst imaginable health state'. The MMRM included change from baseline in the efficacy parameter as the dependent variable; treatment, protocol-specified visits, treatment-by-visit interaction, and amyloid positivity as the fixed effects; baseline efficacy parameter and baseline age as covariates; and measures within-patient at each visit as a repeated measure. An unstructured variance-covariance matrix was used. The following factors may also have been included in the model: ApoE carrier status, baseline use of AD symptomatic medication and clinical subgroup - MCI or vmAD, if found to be significantly associated with the response measure (p \< 0.15).

Time frame:
Part A (Week 50A and Week 104A)
Reported as:
Least squares mean · score on a scale
EuroQol 5 Dimensions 5 Levels - Visual Analogue Scale (EQ-5D-5L - VAS) Score
score on a scalePlacebo Arm Part AABvac40 Arm Part A
Week 50A-4.77 ± 2.355-4.92 ± 2.323
Week 104A-5.22 ± 3.114-1.08 ± 3.093
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.9609
  • Placebo Arm Part A vs ABvac40 Arm Part A · Mixed Models Analysis · p = = 0.3310
Other pre-specifiedAverage Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) - Sensitivity

Average maximal increment (MΔ) of plasma anti-Aβ40 antibody signal (optical density \[OD\] in ELISA) in each subject with regard to Baseline visit. Sensitivity analyses in the PP (Part A) analysis set.

Time frame:
Part A (Baseline, and post-Baseline visits at Week 2A, Week 6A, Week 10A, Week 14A, Week 18A, Week 24A, Week 40A, Week 44A, Week 50A, Week 77A, and Week 104A)
Reported as:
Mean · OD
Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) - Sensitivity
ODPlacebo Arm Part AABvac40 Arm Part A
Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) - Sensitivity0.10 ± 0.133.29 ± 0.67
Statistical analysis
  • Placebo Arm Part A vs ABvac40 Arm Part A · t-test, 1 sided · p = < 0.0001 (A 1-sided t-test with a significance level of 0.025 was employed.)
  • Placebo Arm Part A vs ABvac40 Arm Part A · Wilcoxon (Mann-Whitney) · p = < 0.0001
  • Placebo Arm Part A vs ABvac40 Arm Part A · ANCOVA · p = < 0.0001 · Mean difference (final values): 3.21 · 95% CI 3.02 to 3.4

Adverse events

Collected over Whole study duration (Part A+Part B; up to 42 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Arm Part A1/60 (1.7%)16/60 (26.7%)53/60 (88.3%)
ABvac40 Arm Part A1/64 (1.6%)17/64 (26.6%)57/64 (89.1%)
ABvac40 Arm Part B0/37 (0%)6/37 (16.2%)30/37 (81.1%)
Placebo+Booster Arm Part B0/40 (0%)2/40 (5%)30/40 (75%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Amyloid related imaging abnormalitiesNervous system disorders9/608/641/370/40
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/603/640/370/40
Femur fractureInjury, poisoning and procedural complications0/602/640/370/40
Pelvic fractureInjury, poisoning and procedural complications0/600/641/370/40
Venous thrombosis limbVascular disorders0/600/641/370/40
Acute myocardial infarctionCardiac disorders0/600/641/370/40
Atrial fibrillationCardiac disorders1/600/641/370/40
Atrioventricular block completeCardiac disorders0/600/641/370/40
Lacunar infarctionNervous system disorders0/600/640/371/40
Coronavirus infectionInfections and infestations0/600/640/371/40
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlacebo Arm Part AABvac40 Arm Part AABvac40 Arm Part BPlacebo+Booster Arm Part B
Coronavirus infectionInfections and infestations1/604/646/379/40
Urinary tract infectionInfections and infestations3/6011/645/374/40
ErythemaSkin and subcutaneous tissue disorders7/6010/643/370/40
FallInjury, poisoning and procedural complications4/609/640/374/40
HeadacheNervous system disorders7/605/643/373/40
Injection site reactionGeneral disorders4/604/644/373/40
Peripheral swellingGeneral disorders1/601/644/371/40
HypertensionVascular disorders6/603/640/370/40
Injection site erythemaGeneral disorders4/606/643/371/40
PruritusSkin and subcutaneous tissue disorders1/602/643/370/40

Baseline characteristics

Subjects who received Placebo or ABvac40 during Part A.

Age, Continuous
Age, Continuous(years)Placebo Arm Part AABvac40 Arm Part ATotal
Mean70.1 ± 5.4970.6 ± 5.9570.4 ± 5.71
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Arm Part AABvac40 Arm Part ATotal
Female363874
Male262450
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Arm Part AABvac40 Arm Part ATotal
Asian/Pacific islander000
Black000
Caucasian6058118
Other112
Missing134
Study Disease
Study Disease(Participants)Placebo Arm Part AABvac40 Arm Part ATotal
amnestic Mild Cognitive Impairment (a-MCI)423880
Very Mild Alzheimer's disease (VMAD)202444
Amyloid-positron Emission Tomography (a-PET) Status
Amyloid-positron Emission Tomography (a-PET) Status(Participants)Placebo Arm Part AABvac40 Arm Part ATotal
Positive454792
Negative171532
Apolipoprotein E (ApoE) Status
Apolipoprotein E (ApoE) Status(Participants)Placebo Arm Part AABvac40 Arm Part ATotal
Noncarriers: E2/E2 and E2/E3, E3/E3242448
Carriers (Heterozygous: E2/E4, E3/E4)332962
Carriers (Homozygous: E4/E4)5914
Time from Disease Diagnosis to Informed Consent
Time from Disease Diagnosis to Informed Consent(months)Placebo Arm Part AABvac40 Arm Part ATotal
Mean14.48 ± 15.8114.68 ± 13.7114.58 ± 14.74
08

Study locations

23 sites
  • Hôpital François Mitterrand
    Dijon, Bourgogne-Franche-Comté 21000, France
  • CHU de Montpellier
    Montpellier, 34295, France
  • Centre de Recherche Clinique du Gérontopôle
    Toulouse, 31059, France
  • San Giovanni di Dio - Fatebenefratelli
    Brescia, 25125, Italy
  • Hospital General Universitario de Alicante
    Alicante, Alicante 03010, Spain
  • Barcelona Beta Brain Research Center (BBRC)
    Barcelona, Barcelona 08005, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08025, Spain
  • Fundació ACE
    Barcelona, Barcelona 08028, Spain
  • Hospital Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
  • Hospital del Mar
    Barcelona, Barcelona, Spain
  • Hospital Mútua de Terrasa
    Terrassa, Barcelona 08221, Spain
  • Hospital U. de Burgos
    Burgos, Burgos 09006, Spain
  • Hospital Universitario Donosti
    Donostia / San Sebastian, Guipuzcoa 20014, Spain
  • Hospital San Pedro
    Logroño, La Rioja 26006, Spain
  • Hospital Santa Maria de Lleida
    Lleida, Lleida 25198, Spain
  • Hospital Ramón y Cajal
    Colmenar Viejo, Madrid 28034, Spain
  • Complejo Hospitalario Ruber Juan Bravo
    Madrid, Madrid 28006, Spain
  • Hospital Universitario 12 Octubre
    Madrid, Madrid 28010, Spain
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
  • CUN - Clínica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Cae Oroitu
    Algorta, Vizcaya 48993, Spain
  • Hospital Clínico Universitario Lozano Blesa
    Zaragoza, Zaragoza 50009, Spain
  • Karolinska Universitetssjukhuset
    Stockholm, 141 86, Sweden
09

References and documents

Publications

  • Pascual-Lucas M, Lacosta AM, Montanes M, Canudas J, Loscos J, Monleon I, Allue JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whyms D, Terencio J, Pinol-Ripoll G, Boada M. Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Abeta40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study. Alzheimers Dement. 2025 Oct;21(10):e70776. doi: 10.1002/alz.70776. PubMed 41058018 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Mar 2023, 63 months.

Results were first posted in Feb 2025, 1 year 10 months after primary completion.

Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's 63 months is above that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 12, 2018
StartActual
Dec 13, 2017
Primary completionActual
Mar 23, 2023
CompletionActual
Mar 23, 2023
Results first posted
Feb 3, 2025
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03461276
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Dec 13, 2017
Primary completion
Mar 23, 2023
Completion
Mar 23, 2023
Results posted
Feb 3, 2025
Last update
May 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion